Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and provide more health benefits.